Provided herein are compositions, systems, and methods for detecting and treating IL-17 and/or IL-13 related conditions, such as asthma, autoimmune diseases, and cancer. In some embodiments, methods, compositions, and systems are provided for detecting elevated protein or RNA levels of IL-17 (and/or IL-13) and a second marker selected from: SAA, LCN2, and YKL-40, and treating the subject with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor. In other embodiments, methods, compositions, and systems are provided for detecting a biomarker in a sample from a subject that has been treated with an IL-17 (or IL-13) inhibitor or IL-17 (or IL-13) receptor inhibitor, where the biomarker is SAA, LCN2, or YKL-40, and where at least one action is performed, such as identifying elevated levels of the biomarker in the biological sample and treating the subject with an IL-17 (or IL-13) inhibitor and/or IL-17 (or IL-13) receptor inhibitor.

Devices, methods, and kits are provided for allergy testing based on basophil activation in a blood sample. Susceptibility of an individual to an allergic reaction to an allergen is detected by collecting a blood sample from the individual and assaying for activation of basophils in response to stimulation with an allergen. In particular, a microfluidic device is provided for automating the assay for detecting basophil activation as an indication of the susceptibility of an individual to an allergic reaction as well as kits containing such a device and diagnostic methods for using such a device for allergy testing. Additionally, such a microfluidic device can be adapted for multiplexed detection of allergic responses to multiple allergens by performing assays in parallel to detect the basophil responses to each allergen.

Apparatuses and methods of optically analyzing fluid within a pipette are described herein. In an embodiment, an optical reader subassembly includes a pipette configured to aspirate and hold a fluid sample within its tip, a housing configured to receive at least the tip of the pipette through a reentrant seal so that the tip of the pipette is located in a light tight manner within an internal area, a light source positioned to be in proximity to the tip of the pipette when the tip of the pipette is received by the housing, the light source configured to project light through the tip of the pipette and onto the fluid sample held within the tip, and an optical sensor configured to take a reading of the fluid sample held within the tip of the pipette without any of the fluid sample being injected from the pipette.

Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardivacular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.

The current disclosure provides methods and compositions for treating food allergies, infections, autoimmune conditions, and other allergic conditions. Accordingly, the current disclosure relates to a method for treating an infectious, autoimmune, or allergic disease in a subject comprising administering a composition comprising bacterium Anaerostipes caccae to the subject. Further aspects relate to a method for treating a food allergy or for reducing an allergic response to an allergen or for treating or preventing an anaphylactic response in a subject comprising administering a composition comprising bacterium Anaerostipes caccae and a prebiotic to the subject.

Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of eosinophil lineage-committed progenitor (EoP) is elevated in a blood sample obtained from a subject, diagnosing the subject with active EoE when an EoP level in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the EoP level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE. Kits related to same are also disclosed.

The present invention includes a composition and a method of modulating an immune response with a composition that comprises an anti-BAFF receptor antibody or binding fragment thereof that is bound or conjugated to an siRNA, and shRNA, or both, that targets a BAFF receptor mRNA.

An object of the present invention is to provide a measurement method and a reagent for measurement which can measure LRG in a biological sample simply in a short time. The present inventors have intensively studied to achieve the object and made findings that LRG in a biological sample can be measured simply in a short time by an immunoagglutination measurement method in which the biological sample is brought into contact with insoluble carrier particles carrying a first anti-LRG monoclonal antibody and insoluble carrier particles carrying a second anti-LRG monoclonal antibody in a liquid phase, and the invention has been thus completed.

Provided herein are methods of monitoring progression, regression, or stage of an AID in a subject, measuring a level of expression of a gene, an RNA, or a protein, or a combination thereof, in a sample obtained from a niche at the implantation site of a synthetic scaffold in the subject at a first time point and at a second time point, wherein the expression level measured at the first time point is compared to the expression level measured at the second time point, wherein the difference in the level of expression at the second time point relative to the level of expression at the first time point is indicative of progression, regression, or stage of the autoimmune disease. Related methods of detecting an AID, determining treatment for a subject with an AID, determining efficacy of an AID treatment, or treating an AID, are further provided.

The present invention provides methods and compositions for improved diagnosis of shrimp allergies.